SAN FRANCISCO, Nov. 16, 2022 /PRNewswire/ -- Coagulant Therapeutics Corporation, a privately held company focused on the design, development and commercialization of therapeutics targeted to the coagulation cascade and its adjacencies, today announced the acceptance of two abstracts for presentation at the 64th American Society of Hematology (ASH) Annual Meeting, taking place in New Orleans, Louisiana and virtually December 10-13, 2022. Abstract 402 is an oral presentation highlighting Coagulant's unique nanobody library targeting activated protein C (APC) for acute bleeding (e.g. trauma) and adjacencies (e.g. Hemophilia, Ischemia, Sepsis). Abstract 2458 is a poster describing CT-001 activity under coagulopathic conditions, a shared feature of the most fatal acute bleeds.
Coagulant Therapeutics Corporation, a privately held company focused on the research, development and commercialization of therapeutics targeted to...